Leg 500 Assignment 4 Legal and Ethical Considerations in Marketing, Product Safety and Intellectual Property

866 Words Nov 8th, 2015 4 Pages
LEG 500 Assignment 4 Legal and Ethical Considerations in Marketing, Product Safety And Intellectual Property https://hwguiders.com/downloads/leg-500-assignment-4-legal-and-ethical-considerations-in-marketing-product-safety-and-intellectual-property/ LEG 500 Assignment 4 Legal and Ethical Considerations in Marketing, Product Safety And Intellectual Property You are a new associate at the law firm of Dewey, Chetum, and Howe. John, a former researcher at PharmaCARE, comes to your office. He has concerns about PharmaCARE’s use of AD23, one of the company’s top-selling diabetes drugs. Two (2) years ago, after PharmaCARE’s research indicated that AD23 might also slow the progression of Alzheimer’s disease, John and his team of …show more content…
The company ignored this data and continued filling large orders and paying huge bonuses to all the executives and managers, including John, whose wife recently died from a heart attack after using AD23. John has come to you with an internal company memo describing the potential problems with AD23, and information describing the company’s willingness “roll the dice” and continue to market the drug.
Your senior partner has asked you to write a memo outlining the following issues for review by the senior partners.
In preparation for this assignment, use the Internet or Strayer Library to research examples of intellectual property theft that occurred within the past two (2) years.

Write an eight to ten (8-10) page paper in which you:
1.Research three to five (3-5) ethical issues relating to marketing and advertising, intellectual property, and regulation of product safety and examine whether PharmaCARE violated any of the issues in question.
2.Argue for or against Direct-to-Consumer (DTC) marketing by drug companies. Provide support for your response.
3.Determine the parties responsible for regulating compounding pharmacies under the current regulatory scheme, the actions that either these parties or the FDA could / should have taken in this

Related Documents